Simcere Pharmaceutical Group Limited (2096) announced a further revision of the annual caps under its Exclusive Promotion Services Cooperation Agreement with Beijing Simcere Sanroad, primarily due to the rapid increase in promotion service fees tied to the generic Fumarate Bedaquiline Tablets. The first revised caps for 2025 and 2026 were RMB65 million and RMB100 million, respectively, but actual transaction amounts had reached nearly RMB59.71 million by the end of September 2025 for the current year alone. To accommodate the higher-than-expected demand—driven by expanded government centralized procurement and broader hospital coverage—the annual caps have been further raised to RMB100 million in 2025 and RMB150 million in 2026.

According to the board, the revised figures are based on actual transaction data, ongoing market expansion, and growing hospital coverage for the product under promotion. Other terms of the agreement remain unchanged. This transaction constitutes a continuing connected transaction, and it is subject to reporting, announcement, and annual review requirements but exempt from independent shareholders’ approval under Chapter 14A of the Listing Rules.